Drug Profile
Research programme: antibody therapeutics - HiFiBiO/Pfizer
Latest Information Update: 28 Jun 2022
Price :
$50
*
At a glance
- Originator HiFiBiO; Pfizer
- Class Antibodies; Antineoplastics
- Mechanism of Action Immunosuppressants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Autoimmune disorders; Cancer
Most Recent Events
- 28 Jun 2022 No recent reports of development identified for research development in Autoimmune-disorders in USA
- 28 Jan 2019 No recent reports of development identified for research development in Cancer in USA
- 16 May 2018 Early research in Autoimmune disorders in USA (unspecified route), before May 2018